Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop
Top Cited Papers
- 31 October 2001
- journal article
- Published by Elsevier BV in Controlled Clinical Trials
- Vol. 22 (5), 485-502
- https://doi.org/10.1016/s0197-2456(01)00153-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Meta-analysis for the evaluation of potential surrogate markersStatistics in Medicine, 1997
- ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKERStatistics in Medicine, 1997
- Perspective: Validating Surrogate Markers--Are We Being Naive?The Journal of Infectious Diseases, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDSJournal of the American Statistical Association, 1995
- Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and aids researchStatistics in Medicine, 1994
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989